[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dialysis-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dialysis-patients":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,69,101,123,155,186,214],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100636110","comparisons-of-biochemical-and-clinical-outcomes-of-hemodialysis-patients-treated-with-middle-cut-off-dialyzers-versus-high-flux-hemodialysis-or-hemodiafiltration-100636110",false,"NCT07561424","Comparisons Of Biochemical And Clinical Outcomes Of Hemodialysis Patients Treated With Middle Cut-Off Dialyzers Versus High-Flux Hemodialysis Or Hemodiafiltration","CONCORDIA","Inclusion Criteria\n\n* 18 years of age or older\n* Treated at an in-centre dialysis clinic\n* Receiving chronic, maintenance HD","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","The CONCORDIA study is a retrospective, observational study evaluating clinical and biochemical outcomes among patients receiving maintenance hemodialysis with medium cut-off (MCO) dialyzers (Theranova) compared with high-flux hemodialysis (HF-HD) and hemodiafiltration (HDF). Using real-world data from non-DOPPS Theranova sites and the DOPPS cohort as an external control, the study aims to assess whether MCO dialyzers are associated with improved outcomes versus HF-HD and non-inferior outcomes compared with HDF. The primary outcome is all-cause mortality, with secondary outcomes including cardiovascular events, hospitalizations, infections, and laboratory measures related to anemia, mineral metabolism, and inflammation.",[24,25],"ESKD","Dialysis Patients",[27,28],"dialysis","HDF","RECRUITING","2026-04-28",{"date":32,"type":33},"2026-05-01","ACTUAL",{"date":35,"type":33},"2026-02-01",{"date":37,"type":20},"2026-09-01",{"name":39,"class":40},"Arbor Research Collaborative for Health","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100635865","carotid-intima-media-thickness-in-dialysis-patients-and-traditional-risk-factors-100635865","NCT07558239","Carotid Intima-media Thickness in Dialysis Patients and Traditional Risk Factors","Association of Traditional Cardiovascular and Dialysis-Specific Risk Factors With Carotid Intima-Media Thickness in Hemodialysis Patients: A Cross-Sectional Study\"","Inclusion Criteria:\n\n* 1\\. Age 18 or older. 2. Patients with sepsis without AKI at the time of admission.\n\nExclusion Criteria:\n\n* o Active malignancy\n\n  * Acute infections\n  * Recent cardiovascular events (\\\u003C3 months)\n  * Poor echocardiographic window for CIMT measurement","70 Years",{"count":51,"type":20},100,"* Cardiovascular disease (CVD) is the leading cause of mortality in hemodialysis (HD) patients.\n* Carotid intima-media thickness (CIMT) is a validated surrogate marker for atherosclerosis.\n* Both traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia) and dialysis-specific factors (mineral metabolism disorders, dialysis duration) contribute to vascular damage.",[25,54,55],"Hypertension","Atherosclerosis",[57,58],"Renal dialysis","Carotid intima- media thickness","NOT_YET_RECRUITING","2026-04-23",{"date":62,"type":33},"2026-04-30",{"date":64,"type":20},"2026-04-24",{"date":66,"type":20},"2026-07-01",{"name":68,"class":40},"Minia University",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":41},"100628262","can-changes-in-dialysate-sodium-concentration-improve-blood-pressure-and-endothelial-function-in-chronic-hd-patients-100628262","NCT07459348","Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Chronic HD Patients?","Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Patients Undergoing Chronic Hemodialysis?","NADI","Inclusion Criteria:\n\n* Adults receiving chronic in-center hemodialysis at Regional Hospital Gødstrup\n* Age ≥ 18 years\n* On thrice-weekly hemodialysis for a stable period (as assessed in EPJ)\n* Plasma sodium within the range required for safe participation (as per screening)\n* Able to understand study information and provide written informed consent\n* Eligible based on review of electronic patient record (dialysis duration, frequency, age, p-sodium)\n\nExclusion Criteria:\n\n* Significant cardiac disease that may interfere with participation, including:\n* Heart failure (with clinically relevant instability)\n* Recent acute myocardial infarction (date verified in EPJ)\n* Pacemaker (specific types that interfere with measurements)\n* History of stroke or TCI (date verified in EPJ)\n* Amputation of an extremity (affects body composition measurements)\n* Diabetes with unstable glycemic control or recent major treatment changes\n* Any condition that prevents accurate blood pressure measurement or CO-rebreathing\n* Inability to complete study procedures (questionnaires, monitoring, blood sampling)\n* Expected inability to complete both intervention periods (e.g., planned transfer, transplantation)\n* Declines participation after receiving oral and written information",{"count":78,"type":20},25,"INTERVENTIONAL",[81],"NA","People with end stage kidney disease cannot regulate salt and water normally, which often leads to high blood pressure, fluid overload, and a higher risk of heart disease.\n\nHemodialysis is a life sustaining treatment that removes waste products, excess fluid, and electrolytes from the blood. However, the treatment itself can influence blood pressure and how the blood vessels function. Many patients experience symptoms such as thirst, headaches, fatigue, and swelling, which affect both daily well being and long term health. One possible way to reduce these problems may be as simple as adjusting the amount of sodium in the dialysis fluid.\n\nDuring dialysis, substances move between the patient's blood and the dialysate, the special fluid used in the machine. Sodium is one of the most important components because it helps regulate fluid balance and blood pressure. A higher sodium concentration in the dialysate can make patients feel more thirsty, cause them to drink more, and lead to fluid retention and higher blood pressure. On the other hand, lowering sodium too much can cause dizziness, low blood pressure, cramps, and discomfort during treatment. Because of this, there is ongoing debate about what the \"right\" sodium level should be.\n\nToo much sodium over time may also harm the blood vessels. The inner lining of the vessels, called the endothelium, is protected by a thin layer known as the glycocalyx. This layer helps prevent sodium from entering the vessel wall and supports the production of nitric oxide, a molecule that relaxes blood vessels and reduces inflammation. High salt exposure can damage the glycocalyx and reduce nitric oxide production, making the vessels stiffer and raising blood pressure. In dialysis patients, low nitric oxide levels are linked to worse outcomes and episodes of rising blood pressure during treatment. Some small studies suggest that lowering dialysate sodium can improve blood pressure and endothelial function, but larger studies have not shown clear effects on survival. This indicates that we still do not fully understand which patients benefit most or how sodium changes affect both physical and subjective symptoms.\n\nThis study aims to fill these knowledge gaps by examining how a lower sodium concentration in the dialysate affects blood pressure, blood vessel function, fluid overload, inflammation, and patient reported symptoms. The goal is to provide new insights that could help tailor dialysis treatment to individual patients in a simple and cost effective way.\n\nThe study will compare two sodium concentrations: a lower level (133 mmol\u002FL) and the standard level used in many clinics (139 mmol\u002FL). Twenty five patients receiving chronic in center hemodialysis will participate. Each patient will undergo both treatments for three weeks each, in random order, with a two week washout period in between. This crossover design allows each patient to serve as their own control, making it easier to detect meaningful differences.\n\nThe main outcome is the difference in 24 hour systolic blood pressure between the two sodium levels. Secondary outcomes include changes in nitric oxide levels in the blood, measures of fluid overload using two different techniques, markers of inflammation, arterial stiffness, and patient reported symptoms such as thirst, fatigue, and overall well being. The study will also compare two methods for assessing fluid overload: bioimpedance spectroscopy and a newer carbon monoxide rebreathing technique.\n\nBlood pressure and arterial stiffness will be measured over 44 hours using a portable device. Blood samples will be collected to analyze nitric oxide, inflammatory markers, and sodium handling in red blood cells. Fluid status will be measured using both bioimpedance and the CO rebreathing method. Patients will complete a weekly questionnaire developed together with dialysis patients to capture their experiences and symptoms.",[84,25,85,86],"Dialysis Dependent Chronic Kidney Disease","Sodium Excess","High Blood Pressure",[88,89,90,91,92],"Dialysate Sodium Concentration","Hemodialysis","Blood Pressure Control","Endothelial Function \u002F Nitric Oxide (NOx)","Fluid Overload Assessment (CO Rebreathing & Bioimpedance)","2026-03-11",{"date":95,"type":33},"2026-03-13",{"date":32,"type":20},{"date":98,"type":20},"2029-12-31",{"name":100,"class":40},"Gødstrup Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":79,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":119,"leadSponsor":121,"locationsCount":41},"100601104","outpatient-recovery-from-acute-kidney-injury-requiring-dialysis---2-100601104","NCT07106151","Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2","ORKID-2","Inclusion Criteria:\n\n* AKI-D (not ESKD, as determined by the clinical inpatient nephrology team)\n* Age ≥ 18 years\n* Planned for continued dialysis outside the acute hospital setting (at outpatient dialysis unit\u002FSNF\u002FLTACH, not planned transfer to another short-stay acute care hospital).\n\nExclusion Criteria:\n\n* Pregnant\n* Prisoner\n* Unable to consent and no surrogate decision maker available\n* Clinical team declines to allow approach for study",{"count":109,"type":20},40,[81],"Providing additional information to patients with acute kidney injury who continue dialysis after hospital discharge and to the accepting kidney doctor (nephrologist) who manages their dialysis may be feasible and beneficial. This study will pilot measuring the patient's residual kidney function at the time of discharge and communicating that result to the accepting nephrologist and the patient, along with information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule.",[113,114,25],"AKI","AKI - Acute Kidney Injury","2026-02-23",{"date":117,"type":33},"2026-02-27",{"date":115,"type":33},{"date":120,"type":20},"2028-01",{"name":122,"class":40},"University of California, San Francisco",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":79,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100613652","intradialytic-exercise-with-blood-flow-restriction-in-hemodialysis-patients-100613652","NCT07269379","Intradialytic Exercise With Blood Flow Restriction in Hemodialysis Patients","Intradialytic Exercise With Blood Flow Restriction by Vascular Occlusion: A New Strategy for Cardioprotection in Hemodialysis Patients","ERO-CARD","Inclusion Criteria:\n\n* Patients aged between 20 and 79 years.\n* Patients on hemodialysis for more than 3 months.\n* No engagement in regular exercise outside of dialysis.\n* No prior exposure to intradialytic exercise within the past six months.\n* No medical contraindications to physical activity.\n* Life expectancy greater than 6 months.\n* Patients with relative good echogenicity\n\nExclusion Criteria:\n\n* Patient is participating in another Category I interventional study, or has participated in another interventional study within the past 3 months\n* The patient is in an exclusion period determined by a previous study\n* The patient is under legal protection or under guardianship or curatorship It turns out to be impossible to give the patient informed information, or the patient refuses to sign the consent\n* Pregnant, parturient or breastfeeding patient\n* Patients with unstable coronary artery disease.\n* Patients with peripheral artery disease (stage III or IV) in the lower limbs.\n* Patients with limb amputation.\n* Patients with musculoskeletal disorders impairing exercise.\n* Presence of a pacemaker, cardiac stimulation device, or implantable cardioverter defibrillator (ICD).\n* History of heart transplant.\n* Patients with uncontrolled hypertension.\n* Refractory anemia.\n* Patients stratified as high risk for deep venous thrombosis","20 Years","79 Years",{"count":134,"type":20},108,[81],"The main objective is to evaluate in hemodialysis patients the effects of two intradialytic rehabilitation programs based on physical exercise, with or without the application of blood flow restriction, on myocardial stunning and morpho-functional cardiac remodelling, compared with usual care (i.e., dialysis without exercise). In addition, the investigators will also assess the acute effects (i.e., a single session for each condition) of physical exercise, with or without blood flow restriction, on myocardial stunning at the end of dialysis.\n\nIn comparison with a conventional exercise program, the combination of physical exercise with blood flow restriction, which synergistically and additively activates intramuscular signalling pathways related to both exercise and ischaemia, is hypothesised to result in:\n\n1. A greater intradialytic cardioprotection, as demonstrated by a greater reduction in myocardial stunning at the end of dialysis (both in acute and chronic applications), with underlying mechanisms involving systemic and neuro-humoral pathways;\n2. Significant improvements in morpho-functional cardiac remodelling, attenuation of arrhythmic disturbances, and enhancement of aerobic capacity, muscle strength, and muscle mass-effects not observed with exercise alone without blood flow restriction, considering the low exercise intensity used in the current rehabilitation program (chronic application only).\n\nThis is a three-arm randomised clinical trial with parallel groups: standard hemodialysis (HD-CONTChro), a rehabilitation program with intradialytic exercise without vascular occlusion (HD-EXChro), and a rehabilitation program with intradialytic exercise with vascular occlusion (HD-BFREChro), with a 1:1:1 allocation ratio.\n\nTo investigate the acute effects of the interventions, all patients will undergo, in a randomized order, one session of each of the three dialysis modalities-standard hemodialysis (HD-CONTacute), hemodialysis with exercise without vascular restriction (HD-EXacute), and hemodialysis with exercise with vascular restriction (HD-BFREacute)-prior to initiation of the chronic phase of the study.",[25],[139,140,141,142,143,144],"end stage renal disease","hemodialysis","blood flow restriction exercise","intradialytic exercise","regional myocardial function","hemorheology","2025-12-05",{"date":147,"type":33},"2025-12-08",{"date":149,"type":33},"2025-11-06",{"date":151,"type":20},"2028-10-06",{"name":153,"class":40},"University of Avignon",2,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":79,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":41},"100611239","protein-supplementation-during-dialysis-prosed-100611239","NCT07237997","Protein Supplementation During Dialysis (PROSED)","Re-examining Nutrition in Dialysis Patients: Nutritional Losses and the Role of Supplementation (Part 2).","PROSED","Inclusion Criteria:\n\n* Age ≥ 18 years (no upper age limit)\n* Patients receiving maintenance dialysis for ≥ three months\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Anticipated live donor kidney transplant and\u002For kidney recovery within the period of sample collection.\n* Anticipated change of dialysis modality within the period of sample collection\n* Severe malnutrition based on either:\n\n  * Renal 7-point Subjective Global Assessment (SGA) scores of 1-2\n  * Global Leadership Initiative Malnutrition (GLIM) Stage 2\n* Protein-losing enteropathy.\n* Persistent nephrotic syndrome with \\>3g\u002Fday urinary protein loss.\n* Active wounds or burns contributing to protein losses as judged by the investigator.\n* Current active acute inflammatory illness (likely to have catabolic effect in the opinion of the investigator).\n* Current malignancy based on recent (\\\u003C12 months) diagnosis and\u002For active treatment for malignancy and\u002For planned treatment for malignancy, excluding non-melanoma skin cancers.\n* Pregnancy (current or planned within duration of study) or breast feeding.\n* People with swallowing difficulties precluding safe ingestion (International Dysphagia Diet Standardization Initiative (IDDSI) level 0 thin fluid).\n* People receiving intradialytic parenteral nutrition or intra-peritoneal amino acids, or any other forms of artificial feeding\n* People prescribed levodopa\n* People who are receiving chronic glucocorticoid therapy (\\>10mg day prednisolone or equivalent for \\>7 days within preceding 90 days).\n* People who are consuming a protein dietary intake above 1.5g protein\u002Fkg\u002Fbody weight.\n* People who, in the opinion of the investigator, will be unable to comply with study protocol requirements.\n* People who are vegan or other religious based dietary restrictions which would prevent them taking the supplement.",{"count":164,"type":20},114,[81],"When a patient has dialysis some nutrients are lost in the process. Nutritional losses include protein, trace elements (i.e. zinc, copper and selenium) and water-soluble vitamins (Vitamins C and B). These nutrients are essential for normal body function, including a good immune system and nutritional status. For example, on average the protein losses during a dialysis session (the process where the blood is cleaned via a machine and special fluid) is equal to 6g of protein\u002Fday (which is the equivalent of the amount of protein in 1 egg). Protein needs for the general population are 0.8g protein per kg of body weight. Because people on dialysis lose protein via the dialysis, it is thought that these people need to eat more protein. Currently, in clinical practice for people receiving dialysis, the guidelines are to aim for 1.1 -1.4g of protein per kg of body weight. However, the research is old and very weak.\n\nDialysis treatments have changed over the past 40 years, and the investigator does not know if the replacement of these nutritional losses is important to how well people do on dialysis and if they have any effect on survival. Previous research is mostly limited to haemodialysis (a type of dialysis that requires a machine which cleans the patients' blood via special filters) and peritoneal dialysis (this is a type of dialysis which happens via the patients' tummy). There is no research on the nutritional supplementation in home HD and nocturnal HD. Our research will investigate if a higher protein provision leads to a reduction is hospital admissions and improved outcomes in patients receiving dialysis.",[25,168,169,170,171,172,173,174,175,176],"Dialysis","Protein Energy Wasting","Protein Intake","High Protein Dietary Intake","Diet","Diet Therapy","Hospitalisation","Muscle Mass and Strength","Muscle Mass","2025-11-14",{"date":179,"type":33},"2025-11-20",{"date":181,"type":20},"2026-01-05",{"date":183,"type":20},"2029-10-30",{"name":185,"class":40},"University of Nottingham",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":79,"phases":197,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100605405","phase-4-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-on-sarcopenia-in-hemodialysis-patients-100605405","NCT07162090","Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients","Observation of the Impact of Hypoxia - Inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients","HIF-PHI","Inclusion Criteria:\n\n* Age: 18 to 80 years old (inclusive), gender unrestricted.\n* End-stage renal disease and maintenance hemodialysis for at least 16 weeks.\n* The average Hb level is 7.0\\~10.0 g\u002FdL (the last two evaluations).\n* And have not received or have discontinued ESA\u002Froxadustat treatment.\n* Vascular access: internal fistula or long-term hemodialysis catheter.\n* Weight between 45-100 kg.\n* Sarcopenia Diagnosis (Reference: AWGS 2019 Consensus):\n* Decreased muscle strength: Male grip strength \\\u003C 28 kg, female grip strength \\\u003C 18 kg.\n* Muscle mass decline: Assessed by bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA), it is characterized by appendicular skeletal muscle mass index (ASMI): \\\u003C 7.0 kg\u002Fm² for men and \\\u003C 5.7 kg\u002Fm² for women (BIA standard, the device and formula used should be specified).\n* Sarcopenia can be diagnosed when both \"decreased muscle strength\" and \"reduced muscle mass\" are present. If resources permit, \"decreased physical function\" (such as a 6-meter walking speed \\\u003C 1.0 m\u002Fs) can be added as an indicator for severity grading.\n* Voluntary participation in this study.\n* Must be able to swallow tablets。\n\nExclusion Criteria:\n\n* Non-renal anemia: Anemia caused by other main reasons (such as thalassemia, megaloblastic anemia due to vitamin B12 or folic acid deficiency, active bleeding, hemolytic anemia, hematological malignancies, etc.).\n* Contraindications and related risks of Roxadustat:\n* People who are allergic to roxadustat or any of its excipients.\n* Uncontrolled hypertension (sitting systolic blood pressure remains \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg after active antihypertensive treatment).\n* There have been thrombotic events such as acute myocardial infarction, unstable angina pectoris, stroke, deep vein thrombosis or pulmonary embolism within the past six months.\n* Those with known active malignant tumors or undergoing anti-tumor treatment (except for basal cell carcinoma, etc.) are excluded.\n* Diseases affecting muscle metabolism and assessment:\n* Severe thyroid dysfunction (uncontrolled).\n* Diagnosed with chronic liver cirrhosis, acute exacerbation of chronic obstructive pulmonary disease (COPD), congestive heart failure (NYHA class IV), and other chronic diseases that seriously affect muscle metabolism.\n* Due to severe limitations in limb movement caused by rheumatoid arthritis, Parkinson's disease, spinal cord injury, etc., it is impossible to complete muscle strength and functional tests.\n* Long-term and excessive use of glucocorticoids (equivalent to prednisone \\> 7.5 mg\u002Fday) or other drugs that may affect muscle metabolism (such as androgens).\n* Other serious systemic diseases:\n* Severe liver dysfunction (Child-Pugh grade C or ALT\u002FAST \\> 3 times the upper limit of normal).\n* Active, uncontrolled severe infection.\n* Life expectancy is less than one year.\n* Special circumstances related to the research:\n* A kidney transplant is planned within the next six months.\n* Has participated in any other interventional clinical trials within the past 3 months.\n* Poor compliance and special populations:\n* There are mental or cognitive impairments, making it impossible to understand or cooperate with the research.\n* Pregnant or lactating women, or women of childbearing age who are unwilling to take effective contraceptive measures during the study period.","80 Years",{"count":196,"type":20},60,[198],"PHASE4","Sarcopenia, abbreviated as muscle loss, is a prevalent complication among patients with chronic kidney disease (CKD), particularly those with end - stage renal disease (ESRD). It significantly impacts patients' quality of life. The prevalence of sarcopenia in patients receiving maintenance hemodialysis (MHD) ranges from 32.7% to 73.5%, which is substantially higher than that in the general population (5% - 13%). Sarcopenia significantly elevates the mortality risk in MHD patients. Specifically, sarcopenia patients experience an increased all - cause mortality rate, a heightened risk of cardiovascular events, a decline in quality of life, and an augmented risk of falls and fractures. A close pathophysiological relationship exists between the hypoxia - inducible factor - 1 (HIF - 1) pathway and sarcopenia. HIF - 1α serves as a key transcription factor for cells to respond to hypoxic conditions. Under normoxic conditions, HIF - 1α is hydroxylated by prolyl hydroxylase (PHD) and subsequently undergoes ubiquitination - mediated degradation. Conversely, under hypoxic circumstances, HIF - 1α is stably expressed, translocates into the nucleus, and activates downstream target genes. HIF - 1α promotes the expression of genes associated with glycolysis, such as GLUT1 and LDHA, while inhibiting mitochondrial oxidative phosphorylation. This results in a shift of skeletal muscle energy metabolism from aerobic to anaerobic pathways. Research has revealed that the protein level of HIF - 1α is significantly decreased in sarcopenia patients. Roxadustat capsules, an oral medication, represent the world's first small - molecule hypoxia - inducible factor prolyl hydroxylase inhibitor (HIF - PHI) developed for the treatment of renal anemia. The physiological function of HIF - 1α not only enhances the expression of erythropoietin but also upregulates the expression of erythropoietin receptors and proteins involved in promoting iron absorption and circulation. Theoretically, roxadustat has the potential to improve sarcopenia. However, due to its prominent effect on anemia correction, it is currently only clinically applicable to anemic patients. This study aims to use ESA as a control to investigate the effect of roxadustat on sarcopenia in hemodialysis patients during the treatment of renal anemia.",[201,202,25],"Sarcopenia","Anemia Associated With Chronic Kidney Disease (CKD)",[201,204],"Anemia","2025-09-07",{"date":207,"type":33},"2025-09-09",{"date":209,"type":20},"2025-09-10",{"date":211,"type":20},"2026-12-31",{"name":213,"class":40},"Tianjin Medical University General Hospital",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":131,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":41},"100576911","ai-driven-prediction-of-dialysis-outcome-with-ehr-100576911","NCT06791447","AI-Driven Prediction of Dialysis Outcome With EHR","Predicting Clinical Outcomes in Dialysis Patients Using Electronic Health Records: An AI-Based Approach","Inclusion Criteria:\n\n1. Patients who have been undergoing dialysis (either hemodialysis or peritoneal dialysis) for at least 3 months.\n2. Complete and accessible EHR data, including medical history, laboratory test results, dialysis treatment details, and clinical observations.\n3. Participants must provide informed consent for the use of their health data for research purposes.\n\nExclusion Criteria:\n\n1. Patients with incomplete or missing critical EHR data, including medical history, laboratory results, dialysis data, or treatment details necessary for the study.\n2. Patients who have been on dialysis for less than 3 months, to ensure stable data for outcome prediction.","100 Years",{"count":223,"type":20},1000000,"This is a multi-center, clinical study designed to evaluate the application and effectiveness of an AI-assisted predictive model for outcome of dialysis patients, leveraging multimodal health data.",[25],[25,227],"AI-Assisted Prediction","2025-04-16",{"date":230,"type":33},"2025-04-17",{"date":232,"type":33},"2023-01-01",{"date":234,"type":20},"2025-05-01",{"name":236,"class":40},"The Eye Hospital of Wenzhou Medical University"]